CoChat

COVID-19 y diabetes mellitus: una relación bidireccional

Open access
Lima-Martínez, Marcos M., Carrera Boada, Carlos, Madera-Silva, Marialaura D., Marín, Waleskha, Contreras, Miguel · 2021 · Clínica e Investigación en Arteriosclerosis
Cited by 172

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

El coronavirus 2 del síndrome respiratorio agudo grave (SARS-CoV-2) es el agente causal de la enfermedad por coronavirus 2019 (COVID-19). La diabetes es una de las comorbilidades más frecuentes en personas con COVID-19, con una prevalencia que varía según los estudios entre el 7 y el 30%. Los diabéticos infectados con SARS-CoV-2 tienen una tasa más alta de admisión hospitalaria, neumonía severa y mayor mortalidad en comparación con sujetos no diabéticos. La hiperglucemia crónica puede comprometer la inmunidad innata y la inmunidad humoral. Además, la diabetes se asocia con un estado inflamatorio crónico de bajo grado que favorece el desarrollo de una respuesta inflamatoria exagerada y, por tanto, la aparición del síndrome de distrés respiratorio agudo. Evidencia reciente ha demostrado que el SARS-CoV-2 también es capaz de producir un daño directo al páncreas, que podría empeorar la hiperglucemia e incluso inducir la aparición de diabetes en sujetos previamente no diabéticos. Las estrategias terapéuticas deben dirigirse a facilitar el acceso de los pacientes al sistema sanitario. El control de la glucemia y de las comorbilidades debe ser individualizado a fin de reducir la incidencia de complicaciones y disminuir la carga en los sistemas de salud. En este artículo revisaremos los mecanismos fisiopatológicos que explican la relación bidireccional entre COVID-19 y diabetes mellitus, su implicación en el pronóstico y el manejo de la hiperglucemia en este grupo de pacientes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.arteri.2020.10.001

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 20

  1. Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med., 382, 1708, 10.1056/NEJMoa2002032 · DOI · Paper page
  2. De Almeida-Pititto, 2020, Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis, Diabetol Metab Syndr., 12, 75, 10.1186/s13098-020-00586-4 · DOI · Paper page
  3. Totura, 2015, Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection, mBio., 6, e00638-15, 10.1128/mBio.00638-15 · DOI · Paper page
  4. Iacobellis, 2020, COVID-19 and diabetes: Can DPP4 inhibition play a role?, Diabetes Res Clin Pract., 162, 108125, 10.1016/j.diabres.2020.108125 · DOI · Paper page
  5. Lima, 2010, Sistema renina angiotensina y riesgo cardiometabólico, Rev Venez Endocrinol Metab., 8, 3
  6. Gheblawi, 2020, Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th Anniversary of the Discovery of ACE2, Circ Res., 126, 1456, 10.1161/CIRCRESAHA.120.317015 · DOI · Paper page
  7. South, 2020, COVID-19, ACE2, and the cardiovascular consequences, Am J Physiol Heart Circ Physiol., 318, H1084, 10.1152/ajpheart.00217.2020 · DOI · Paper page
  8. Jaeckel, 2002, Viruses and diabetes, Ann N Y Acad Sci., 958, 7, 10.1111/j.1749-6632.2002.tb02943.x · DOI
  9. Liu, 2020, ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection, Clin Gastroenterol Hepatol., 18, 2128, 10.1016/j.cgh.2020.04.040 · DOI · Paper page
  10. Zhu, 2020, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, Cell Metab., 31, 1068, 10.1016/j.cmet.2020.04.021 · DOI · Paper page
  11. Sharma, 2020, Metformin in COVID-19; a possible role beyond diabetes, Diabetes Res Clin Pract., 164, 108183, 10.1016/j.diabres.2020.108183 · DOI · Paper page
  12. Pal, 2020, Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?, Diabetes Res Clin Pract., 163, 108146, 10.1016/j.diabres.2020.108146 · DOI
  13. Iacobellis, 2020, COVID-19 and diabetes: Can DPP4 inhibition play a role?, Diabetes Res Clin Pract., 162, 108125, 10.1016/j.diabres.2020.108125 · DOI · Paper page
  14. Carboni, 2020, Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?, Med Hypotheses., 140, 109776, 10.1016/j.mehy.2020.109776 · DOI
  15. Bellido, 2020, Consecuencias de la COVID-19 sobre las personas con diabetes, Endocrinol Diabetes Nutr., 67, 355, 10.1016/j.endinu.2020.04.001 · DOI
  16. Pérez, 2020, Insulin therapy in hospitalized patients, Am J Ther., 27, e71, 10.1097/MJT.0000000000001078 · DOI · Paper page
  17. Bornstein, 2020, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol., 8, 546, 10.1016/S2213-8587(20)30152-2 · DOI · Paper page
  18. Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in Covid-19, N Engl J Med., 382, e102
  19. Riddle, 2020, COVID-19 in people with diabetes: Urgently needed lessons from early reports, Diabetes Care., 43, 1378, 10.2337/dci20-0024 · DOI
  20. Vivas, 2020, Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del grupo de trabajo de trombosis cardiovascular de la Sociedad Española de Cardiología, Rev Esp Cardiol., 73, 749, 10.1016/j.recesp.2020.04.006 · DOI

Cited by

See all 172

Metadata

Authors
Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W., & Contreras, M.
Venue
Clínica e Investigación en Arteriosclerosis
Publisher
Elsevier BV
Published
2021-05
Volume
33
Issue
3
Pages
151-157
ISSN
0214-9168 (ISSN-L)
OpenAlex
W3087544127
Cited by
172
References
11
FWCI
3.41
Type
journal article
Language
es
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 y diabetes mellitus: una relación bidireccional. https://app.cochat.ai/papers/10.1016/j.arteri.2020.10.001
The paper
Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W., & Contreras, M. (2021). COVID-19 y diabetes mellitus: una relación bidireccional. Clínica e Investigación en Arteriosclerosis. https://doi.org/10.1016/j.arteri.2020.10.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.